Connect with us

BUSINESS

Neutra Corp (OTCMKTS:NTRR) Scouts For Vertical Integration Push By Integrating New Technology With Its Hemp-Based CBD Enterprise

Published

on

Neutra Corp (OTCMKTS:NTRR) is examining the possibility of integrating new technology with its hemp-derived CBD Enterprise. The company expects that such an addition to its operations would drive growth in the future and promote expansion.

The natural progression of integration efforts

Chief Executive Officer of Neutra, Sydney Jim, said it is a natural progression of the company’s ongoing integration efforts. The company established its retail presence with the takeover of VIVIS in 2019.

VIVIS is a one-stop source for hemp-based nutritional and health products. The company is established to satisfy the growing need for high potency and high-quality hemp-extracted products. Medical grade hemp opens a new chapter in the treatment of anxiety and pain. The customers can use hemp extracts of medical-grade to soothe the pain from diseases such as high-performance athletic injuries and epilepsy. It can also provide comfort from everyday pain and aches. Therefore, the takeover of VIVIS is critical to promote future growth for Neutra.

Neutra plans to accomplish similar success stories through the purchase of land and establish hemp cultivation facilities. Jim said the addition of the technology component to its growing blend strengthens the company and stays competitive in the entire space, say from the lab to the field to the retail store.

Receives fresh equity funding

Neutra has received a fresh tranche of private funding earlier this month. The company could use these funds in its push to acquire a CBD related technology company or partner with such an existing firm. Neutral could improve CBD delivery mechanisms that comprise improved concentrations and absorption rates with the help of CBD related Technology Company.

CBD offers a myriad of medical benefits

The multipurpose and natural hemp-derived compound – CBD offers a myriad of health benefits. According to the feedback received from the users, CBD provides relief from anxiety, pain, slows down the neurodegenerative disorders, reduces the effects of seizures, and mitigates the side effects of cancer treatments. Also, the users of hemp-derived CBD do not face addiction. The market for hemp-derived CBD products expects to reach $22 billion by the year 2022 from the sales of $390 million in 2019.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Trulieve Cannabis Corp (OTCMKTS: TCNNF) Reopens North Port Dispensary, Formerly Harves House of Cannabis

Published

on

Trulieve Cannabis Corp (OTCMKTS: TCNNF) has announced the reopening of a North Port, Florida dispensary. This dispensary located in the Sarasota area is the 92nd Trulieve location in the state and was previously named Harvest House of Cannabis.

Trulieve reopens North Port dispensary. 

When the North Port site reopens as Trulieve, it will greet Harvest patients with the same devoted personnel and high-quality service as when it closed for renovations and rebranding. Trulieve announced the completion of its purchase of Harvest Health and Recreation Inc. on October 1, with all Harvest dispensaries in Florida closed for rebranding to Trulieve. Throughout the month of October, the Company will continue to reopen Harvest sites across Florida.

The company is inviting the community to celebrate the reopening of its dispensary with all-day specials and swag giveaways. On launch day, all patients, from newcomers to long-time Trulieve patients, will be eligible for a 25% discount at the North Port facility.

Patients will find the largest assortment of CBD and THC products in Florida, including edibles, concentrates, smokable flowers, tinctures, vaporizers, topical creams, and more, in stores and online. Trulieve also provides home delivery throughout the state, as well as web-based ordering and in-store pickups.

Products available online and in-store 

Trulieve’s whole product portfolio is available for online orders to aid patients with ordering, with in-store pickup or home delivery options available across the state depending on customer preference. In addition, Trulieve provides complimentary 30-minute virtual consultations with a Trulieve expert to assist with product, device, or doctor’s suggestion questions. Appointments are available on Trulieve’s website and open to all patients, even if they are new to medical cannabis or those searching for new therapeutic choices.

The company is keeping an eye on the COVID-19 situation and is committed to limiting the virus’s spread. Trulieve requires all staff, regardless of vaccination status, to put on masks in addition to following strict cleanliness and safety measures.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

ILUS International Inc. (OTCMKTS: ILUS) Announces Award Of a $1 Million Contract For Phase 2 Burj 2020 Project

Published

on

ILUS International Inc. (OTCMKTS: ILUS) has announced that BDC Fire which it acquired on April 12, 2021, which had received three contract awards estimated at $1.5 million, has now received a $1 million contract for phase 2 of the Burj 2020 Project.

BCD Fie receives another $1 million contract 

BCD Fore had previously received a contract for fire systems installation for the Burj 2020 Tower in Dubai. The company started work on the project inQ3 2020, and the contract value for the phase is around $1 million.

The company is committed to completing the project and upcoming projects, and as a result, it is recruiting an additional 45 technicians and salespeople. Hiring more technicians puts the company in a position to apply for the lucrative A-level license for installation, supply, and maintenance of fire systems in industrial, residential, and oil fields.

ILUS Managing DirectorJohn-Paul Backwell said, “BCD Fire has achieved so much since we acquired it earlier this year and the award of this next phase of the Burj 2020 project is reward for the progress made by the ILUS and BCD teams. Obtaining the A-level license will rocket this acquisition to a whole new level. There has also been overwhelming interest from regional Fire Safety Training Companies in our new Virtual Reality Fire Extinguisher Training Courses which are being launched this month.”

FireBug and TVC received numerous purchase orders 

CEO Nick Link stated, “ILUS just closed out its best quarter yet and we are looking forward to releasing an update on this in the next week or so once the team has finished consolidating the figures. FireBug and TVC have received several purchase orders during the 3rd quarter and they have been making excellent progress, but we have felt it best to provide updates on the more significant deals in the region of $1 million and upwards or noteworthy clients.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Roche Holding Ltd (OTCMKTS: RHHBY) To Present New OCREVUS and ENSPRYNG Data at ECTRIMS 2021

Published

on

Roche Holding Ltd (OTCMKTS: RHHBY) has announced that it will present new ENSPRYNG (satralizumab) and OCREVUS (ocrelizumab) data during the 37th Congress of the European Committee for Treatment and  Research in Multiple Sclerosis.

Roche to present ENSPRYNG and OCREVUS data 

The data comprises 38 abstracts showing new long-terms safety and efficacy data for ENSPRYNG and OCREVUS and the company’s ongoing efforts to assess COVID-19’s impact on people living with multiple sclerosis. More data will shore enhanced scientific understanding of NMOSD and MS in various patient populations, ensuring access to treatment.

Roche’s chief medical officer and global product development head Levi Garraway, said, “The longer-term efficacy and safety data for both OCREVUS and ENSPRYNG reinforce e the impact of these treatments- by significantly slowing disease progression in MS and by preventing debilitating relapses in NMOSD, respectively.  We continue to see that early and ongoing treatment markedly improves outcomes, and we’ll continues to use scientific and real-world insights to improve our understanding and ways to support people living with these neurological disorders.”

Roche to present data from 27 MS studies 

The company will present 27 multiple sclerosis studies that include data showing earlier OCREVUS treatment continues to influence disability progression for around eight years in individuals with primary progressive MS and up to 7.5 years in patients with relapsing MS in the third phase open able trials. In addition, the company will present an updated long-term safety analysis of all clinical studies in RMS  and PPMS patients that will reinforce OCREVUS’ favorable risk-benefit profile.

Roche is focused on addressing health disparities, and the company is optimistic that inclusive research will enhance outcomes and derive insights that can address treatment barriers. The company will present a subgroup analysis of three studies, including CHORDS, ENSEMBLE PLUS, and SaROD in Hispanic, Latino, and African-American populations treated with OCREVUS infusion. Roche is committed to increasing understanding of NMOSD and enhancing care for people living with the condition.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories